Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2003;102:1250-1254
© 2003 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yost, N. P.
Right arrow Articles by Leveno, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yost, N. P.
Right arrow Articles by Leveno, K. J.

ORIGINAL RESEARCH

A Randomized, Placebo-Controlled Trial of Corticosteroids for Hyperemesis Due to Pregnancy

Nicole P. Yost, MD, Donald D. McIntire, PhD, Frank H. Wians, Jr, PhD, Susan M. Ramin, MD, Jody A. Balko and Kenneth J. Leveno, MD

From the University of Texas Southwestern Medical Center, Department of Obstetrics and Gynecology, and Department of Pathology, Dallas, Texas and the University of Texas Houston Medical School, Department of Obstetrics and Gynecology, Houston, Texas.

Address reprint requests to: Nicole P. Yost, MD, University of Texas Southwestern Medical Center, Department of Obstetrics and Gynecology, 5323 Harry Hines Boulevard, Dallas, TX 75390-9032; E-mail: nicole.yost{at}utsouthwestern.edu.

OBJECTIVE: Hyperemesis gravidarum, a severe form of nausea and vomiting due to pregnancy for which there is no proven pharmacological treatment, is the third leading cause for hospitalization during pregnancy. Corticosteroids are commonly used for the treatment of nausea and vomiting due to cancer chemotherapy–induced emesis and might prove useful in hyperemesis gravidarum.

METHODS: A randomized, double-blind, placebo-controlled trial was conducted in 126 women who previously had not responded to outpatient therapy for hyperemesis gravidarum during the first half of pregnancy. Intravenous methylprednisolone (125 mg) was followed by an oral prednisone taper (40 mg for 1 day, 20 mg for 3 days, 10 mg for 3 days, 5 mg for 7 days) versus an identical-appearing placebo regimen. All women also received promethazine 25 mg and metoclopramide 10 mg intravenously every 6 hours for 24 hours, followed by the same regimen administered orally as needed until discharge. The primary study outcome was the number of women requiring rehospitalization for hyperemesis gravidarum.

RESULTS: A total of 110 women delivered at our hospital and had pregnancy outcomes available for analysis; 56 were randomized to corticosteroids and 54 were administered placebo. Nineteen women in each study group required rehospitalization (34% versus 35%, P = .89, for corticosteroids versus placebo, respectively).

CONCLUSION: The addition of parenteral and oral corticosteroids to the treatment of women with hyperemesis gravidarum did not reduce the need for rehospitalization later in pregnancy.




This article has been cited by other articles:


Home page
 Evid. Based Med.Home page
Other articles noted
Evid. Based Med., March 1, 2004; 9(2): 63 - 64.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Obstetricians and Gynecologists.